WO2001018038A3 - Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis - Google Patents

Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis Download PDF

Info

Publication number
WO2001018038A3
WO2001018038A3 PCT/GB2000/003196 GB0003196W WO0118038A3 WO 2001018038 A3 WO2001018038 A3 WO 2001018038A3 GB 0003196 W GB0003196 W GB 0003196W WO 0118038 A3 WO0118038 A3 WO 0118038A3
Authority
WO
WIPO (PCT)
Prior art keywords
snare
cell
bont
snap
resistant
Prior art date
Application number
PCT/GB2000/003196
Other languages
French (fr)
Other versions
WO2001018038A2 (en
Inventor
James Oliver Dolly
Gregory A Sullivan
Nadiem Mohammed
Patrick G Foran
Original Assignee
Imp College Innovations Ltd
James Oliver Dolly
Sullivan Gregory A 0
Nadiem Mohammed
Patrick G Foran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, James Oliver Dolly, Sullivan Gregory A 0, Nadiem Mohammed, Patrick G Foran filed Critical Imp College Innovations Ltd
Priority to AU68526/00A priority Critical patent/AU781226B2/en
Priority to JP2001522260A priority patent/JP2003508092A/en
Priority to EP00956652A priority patent/EP1210444A2/en
Priority to CA002379532A priority patent/CA2379532A1/en
Publication of WO2001018038A2 publication Critical patent/WO2001018038A2/en
Publication of WO2001018038A3 publication Critical patent/WO2001018038A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of treating a patient suffering from poisoning by clostridial toxin wherein a SNARE (soluble (N-ethylmaleimide-sensitive fusion protein)-attachment protein receptor) that is resistant to proteolysis by the said clostridial toxin (toxin-resistant SNARE) and/or is capable of inhibiting the clostridial toxin is supplied to a cell of the patient. The SNARE that is resistant to proteolysis may be, synaptosomal-associated polypeptide of 25 kDA (SNAP-25). The SNAP-25 is preferably resistant to proteolysis by BoNT/A, BoNT/E and BoNT/C. A method of treating a patient in need of inhibition of SNARE-dependent exocytosis from a cell capable of performing SNARE-dependent exocytosis wherein a derivative (inhibitory SNARE) that is capable of inhibiting SNARE-dependent exocytosis is supplied to the said cell of the patient. The inhibitory SNARE may be a fragment of SNAP-25 that is derivable by cleavage of SNAP-25 by botulinum toxin A (BoNT/A). The cell may be, for example, a nerve cell, adreno-chromaffin cell or insulin-secreting cell. The SNARE may be supplied to the cell by expressing recombinant polynucleotide construct. The SNARE or construct may be targeted to a nerve cell, by means of an inactive clostridial neurotoxin. The SNARE may be expressed under the target cell-specific promoter.
PCT/GB2000/003196 1999-08-20 2000-08-18 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis WO2001018038A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU68526/00A AU781226B2 (en) 1999-08-20 2000-08-18 Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis
JP2001522260A JP2003508092A (en) 1999-08-20 2000-08-18 Isoforms of SNARE molecules and their use in regulating cellular exocytosis
EP00956652A EP1210444A2 (en) 1999-08-20 2000-08-18 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
CA002379532A CA2379532A1 (en) 1999-08-20 2000-08-18 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14999399P 1999-08-20 1999-08-20
US60/149,993 1999-08-20

Publications (2)

Publication Number Publication Date
WO2001018038A2 WO2001018038A2 (en) 2001-03-15
WO2001018038A3 true WO2001018038A3 (en) 2001-10-11

Family

ID=22532674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003196 WO2001018038A2 (en) 1999-08-20 2000-08-18 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis

Country Status (5)

Country Link
EP (1) EP1210444A2 (en)
JP (1) JP2003508092A (en)
AU (1) AU781226B2 (en)
CA (1) CA2379532A1 (en)
WO (1) WO2001018038A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CA2588758C (en) 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
EP2649985A1 (en) * 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2836193B1 (en) * 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
CA2969463A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
KR102274841B1 (en) * 2019-10-16 2021-07-12 주식회사 하울바이오 Anti-SNAP 25 antibodies inhibiting SNARE complex and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032738A1 (en) * 1994-05-31 1995-12-07 Allergan, Inc. Modification of clostridial toxins for use as transport proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032738A1 (en) * 1994-05-31 1995-12-07 Allergan, Inc. Modification of clostridial toxins for use as transport proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUNSD D., ENGERS S., YANG C., OSSIG R., JEROMIN A., JAHN R.: "Inhibition of transmiter release correlated with the proteolytic activity of tetanus toxin and botulinum toxin A in individual cultured synapsys of Hirudo medicinalis", JOURNAL OF NEUROSCIENCE, vol. 17, no. 6, 15 March 1997 (1997-03-15), pages 1898 - 1910, XP002159205 *
GONELLE-GISPERT C., HALBAN, P. A., NIEMANN H., PALMER M., CATSICAS S., SADOUL K.: "SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion.", BIOCHEMISTRY JOURNAL, vol. 339, 1 April 1999 (1999-04-01), pages 159 - 165, XP002159203 *
SADOUL K., BERGER A., NIEMANN H., WELLER U., ROCHE P.A., KLIP A., TRIMBLE W.S., REGAZZI R., CATSICAS S., HALBAN P.A:: "SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 52, 26 December 1997 (1997-12-26), pages 33023 - 33027, XP002159204 *

Also Published As

Publication number Publication date
AU6852600A (en) 2001-04-10
CA2379532A1 (en) 2001-03-15
JP2003508092A (en) 2003-03-04
AU781226B2 (en) 2005-05-12
EP1210444A2 (en) 2002-06-05
WO2001018038A2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
WO2001018038A3 (en) Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
US20240018500A1 (en) Degradable clostridial toxins
WO2014079495A1 (en) Methods for the manufacture of proteolytically processed polypeptides
Pellegrini et al. Fusion complex formation protects synaptobrevin against proteolysis by tetanus toxin light chain
US20220010294A1 (en) Novel recombinant botulinum neurotoxins with increased duration of effect
EP3333179A1 (en) Novel recombinant botulinum toxin with accelarated onset of effect
AU2015261716B2 (en) Degradable clostridial toxins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 68526/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2379532

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000956652

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000956652

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 68526/00

Country of ref document: AU